Notably, the PDE4 inhibitor rolipram did not have a significant growth inhibitory effect on the zardaverine-sensitive HCC cell line SMMC-7721, which has a relatively low level of PDE4D expression. This evidence concerns the gene PDE4D and hepatocellular carcinoma.